Anhco Nguyen
Chief Tech/Sci/R&D Officer at ATARA BIOTHERAPEUTICS, INC.
Net worth: 653 330 $ as of 2024-03-30
Profile
Anhco Nguyen's current job is as the Executive VP, Chief Scientific & Technical Officer at Atara Biotherapeutics, Inc. Dr. Nguyen's former jobs include being the Vice President-Research & Development at Enumeral Biomedical Holdings, Inc. from 2014 to 2016, an Associate at the Center for Cancer Research at Massachusetts Institute of Technology, and a Vice President at Fate Therapeutics, Inc. Dr. Nguyen's education includes a doctorate from the University of Washington and an undergraduate degree from Harvard College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-03 | 941,397 ( 0.73% ) | 653 330 $ | 2024-03-30 |
Anhco Nguyen active positions
| Companies | Position | Start |
|---|---|---|
| ATARA BIOTHERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2021-05-09 |
Former positions of Anhco Nguyen
| Companies | Position | End |
|---|---|---|
| ENUMERAL BIOMEDICAL HOLDINGS INC | Chief Tech/Sci/R&D Officer | 2016-08-16 |
| Massachusetts Institute of Technology | Corporate Officer/Principal | - |
| FATE THERAPEUTICS, INC. | Corporate Officer/Principal | - |
Training of Anhco Nguyen
| University of Washington | Doctorate Degree |
| Harvard College | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| FATE THERAPEUTICS, INC. | Health Technology |
| ATARA BIOTHERAPEUTICS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Enumeral Biomedical Holdings, Inc.
 Enumeral Biomedical Holdings, Inc. BiotechnologyHealth Technology Enumeral Biomedical Holdings, Inc. is a biopharmaceutical company, which engages in the business of discovering and developing novel antibody immunotherapies for the treatment of cancer and other diseases. It also focuses on the development of a pipeline of next generation monoclonal antibody drugs targeting established and novel immuno-modulatory receptors. The company was founded by Barry C. Buckland, John J. Rydzewski, and Arthur H. Tinkelenberg on December 11, 2009 and is headquartered in Arlington, MA. | Health Technology |
- Stock Market
- Insiders
- Anhco Nguyen
